Craft

Cardax

Stock Price

$0

2024-10-29

Market Capitalization

$883

2024-10-29

Revenue

$710.9 K

FY, 2019

Cardax Summary

Company Summary

Overview
Cardax develops and commercializes safe anti-inflammatory dietary supplements and drugs. Cardax is initially focusing on astaxanthin, which is a powerful and safe naturally occurring anti-inflammatory without the side effects of currently marketed anti-inflammatories. The safety and efficacy of Cardax's products have not been directly evaluated in clinical trials or confirmed by the FDA.
Type
Public
Status
Active
Founded
2006
HQ
Honolulu, HI, US | view all locations
Website
https://cardaxpharma.com/
Cybersecurity rating
Sectors

Key People

  • David G. Watumull, President and CEO, Director

    LocationsView all

    1 location detected

    • Honolulu, HI HQ

      United States

      2800 Woodlawn Dr

    Cardax Financials

    Summary Financials

    Revenue (Q1, 2021)
    $104.6K
    Gross profit (Q1, 2021)
    $66.2K
    Net income (Q1, 2021)
    ($1.4M)
    Cash (Q1, 2021)
    $58.7K
    EBIT (Q1, 2021)
    ($771.3K)
    Enterprise value
    $3.3M

    Footer menu